Objectives The additional impact of coexisting Sjögren’s syndrome (SS) on cardiac involvement in patients with systemic lupus ...
Objective Fatigue is a common, multifaceted symptom in SLE which is difficult to treat. There has been a lack of broadly ...
Objective We aimed to characterise differences in the occurrence of maternal cardiovascular events (CVEs) and adverse ...
Moreover, as some clinical trials have excluded them, the efficacy of some immunosuppressants for this subset of patients has not been strictly confirmed. In this study, we aimed to investigate the ...
Background SLE features aberrant type I interferon production, with the stimulator of interferon genes (STING) pathway acting as a key upstream driver. However, its expression patterns in patients ...
The association between SLE and composite stroke, ischaemic stroke and haemorrhagic stroke remains incompletely understood. This meta-analysis aims to assess the risk of stroke in patients with ...
Background Global collaboration is a key driver of advances in complex diseases such as lupus, yet its distribution and ...
Objective To identify factors associated with individual Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index (SDI) accrual items in 1385 patients from the ...
Background Systemic lupus erythematosus (SLE) is a chronic autoimmune disease influenced by multiple factors. Growing evidence suggests that adverse childhood experiences (ACEs) and post-traumatic ...
Objective To assess the appropriateness of expanded serological activity eligibility criteria for belimumab use in the UK systemic lupus erythematosus (SLE) population (and possibly other countries), ...
Objectives To assess the prevalence of sarcopenia and examine its association with clinical features, health-related quality of life (HRQoL), muscle-specific strength and body composition in patients ...
1702 Patients enrolled in the accelerating medicines partnership (AMP) RA/SLE network with isolated renal disease report minimal quality of life impairment on PROMIS-29 compared to patients with ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results